Search Results Search Sort by RelevanceMost Recent Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607. History of Medicine May 2019 Will We Code for Default ECMO? Daniel J. Brauner, MD and Christopher J. Zimmermann, MD CPR has become default treatment for all patients in cardiac arrest. The history of how this happened demonstrates the power of CPT coding. AMA J Ethics. 2019;21(5):E443-449. doi: 10.1001/amajethics.2019.443. Policy Forum May 2019 What Should We Learn From Early Hemodialysis Allocation About How We Should Be Using ECMO? Daniel Gutteridge, MD and Gabriel T. Bosslet, MD, MA Early hemodialysis allocation deliberations can inform deliberative democratic methods for setting criteria for and guiding policy making about ECMO. AMA J Ethics. 2019;21(5):E421-428. doi: 10.1001/amajethics.2019.421. Personal Narrative Jun 2019 One Resident’s Recommendations for Responding to Unjust Patient Bias Christian A. Pean, MD, MS and Dionne Hart, MD An orthopedic surgery physician’s experiences suggest strategies for addressing patients’ discriminatory behaviors or speech. AMA J Ethics. 2019;21(6):E530-535. doi: 10.1001/amajethics.2019.530. Personal Narrative Jun 2019 Health Risks of Practicing Correctional Medicine Dionne Hart, MD Correctional facilities’ physician employees are at risk for burnout, posttraumatic stress, and suicide. Prison reform should address needs of inmates and staff. AMA J Ethics. 2019;21(6):E540-545. doi: 10.1001/amajethics.2019.540. Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838. Letter to the Editor Oct 2019 Response to “Will We Code for Default ECMO?”: Clarifying the Scope of Do-Not-ECMO Orders Jacob A. Blythe, MA, Sarah E. Wieten, PhD, and Jason N. Batten, MD, MA The authors further consider the merits of preventing ECMO from becoming a default treatment. AMA J Ethics. 2019;21(10):E926-929. doi: 10.1001/amajethics.2019.926. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607.
History of Medicine May 2019 Will We Code for Default ECMO? Daniel J. Brauner, MD and Christopher J. Zimmermann, MD CPR has become default treatment for all patients in cardiac arrest. The history of how this happened demonstrates the power of CPT coding. AMA J Ethics. 2019;21(5):E443-449. doi: 10.1001/amajethics.2019.443.
Policy Forum May 2019 What Should We Learn From Early Hemodialysis Allocation About How We Should Be Using ECMO? Daniel Gutteridge, MD and Gabriel T. Bosslet, MD, MA Early hemodialysis allocation deliberations can inform deliberative democratic methods for setting criteria for and guiding policy making about ECMO. AMA J Ethics. 2019;21(5):E421-428. doi: 10.1001/amajethics.2019.421.
Personal Narrative Jun 2019 One Resident’s Recommendations for Responding to Unjust Patient Bias Christian A. Pean, MD, MS and Dionne Hart, MD An orthopedic surgery physician’s experiences suggest strategies for addressing patients’ discriminatory behaviors or speech. AMA J Ethics. 2019;21(6):E530-535. doi: 10.1001/amajethics.2019.530.
Personal Narrative Jun 2019 Health Risks of Practicing Correctional Medicine Dionne Hart, MD Correctional facilities’ physician employees are at risk for burnout, posttraumatic stress, and suicide. Prison reform should address needs of inmates and staff. AMA J Ethics. 2019;21(6):E540-545. doi: 10.1001/amajethics.2019.540.
Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838.
Letter to the Editor Oct 2019 Response to “Will We Code for Default ECMO?”: Clarifying the Scope of Do-Not-ECMO Orders Jacob A. Blythe, MA, Sarah E. Wieten, PhD, and Jason N. Batten, MD, MA The authors further consider the merits of preventing ECMO from becoming a default treatment. AMA J Ethics. 2019;21(10):E926-929. doi: 10.1001/amajethics.2019.926.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.